Immune thrombocytopenia (ITP): vizsgálatok itt: Kína
65 of 69 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- Korai 1. fázisTaking peopleAn Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT07174843 - 1/2. fázisTaking peopleA Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- Where
- Guangzhou, Jinan, Tianjin, Wuhan
- Életkor
- 18 év to 64 év
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06721013 · EU 2024-518502-40-00 - 3. fázisTaking peopleA Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 171 worldwide
- Run by
- Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00 - 3. fázisTaking peopleA Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00 - No phaseNot yet taking people in KínaClinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
- Where
- Nanchang
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Nanjing Miracle Biotechnology Co., Ltd.
See details and how to joinNCT07811622 - 2. fázisTaking peopleSG301-SC Injection Safety Study in Subjects With Primary ITP Patients
- Where
- Baoding, Changzhi, Chengde, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Jining, Kunming, Liuzhou, Pingdingshan, Siping, Tangshan, Tianjin, Wenzhou, Wuhan, Xian, Xiangyang, Yulin, Zhenzhou
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT07710248 - 4. fázisTaking peopleMulti-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 38
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07788456 - 1/2. fázisTaking peopleA Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
- Where
- Beijing, Bengbu, Nanchang, Tangshan, Tianjin, Xi’an, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 56
- Run by
- Jiangsu BioJeTay Biotechnology Co., Ltd.
See details and how to joinNCT06929299 - 2. fázisNot yet taking people in KínaEltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
- Where
- Tianjin
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07687134 - No phaseNot yet taking people in KínaAtorvastatin Combined With NAC Plus Romiplostim for Management of ITP
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Peking University People's Hospital
See details and how to joinNCT07662525 - 2/3. fázisTaking peopleSirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 164
- Run by
- Chinese SLE Treatment And Research Group
See details and how to joinNCT07657793 - 1. fázisTaking peopleRN1201 Injection in the Treatment of Antibody-Mediated Diseases
- Where
- Suzhou
- Életkor
- 16 év to 65 év
- People
- 9
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07072247 - 1. fázisTaking peopleIASO-782 in Autoimmune Hematological Diseases
- Where
- Tianjin, Wuhan
- Életkor
- 18 év to 65 év
- People
- 16
- Run by
- Shanghai IASO Biotechnology Co., Ltd
See details and how to joinNCT06534021 - 1. fázisTaking peoplePhase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 10
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07206758 - No phaseTaking peopleRomiplostim for Oral TPO-RA Resistant ITP
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 60
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07612319 - 1. fázisNot yet taking people in KínaUniversal STAR-T Cell Injection in R/R Autoimmune Diseases.
- Where
- Haidian
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- Jian Zhu
See details and how to joinNCT07599280 - 3. fázisNot yet taking people in KínaATRA for Management of Primary ITP
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 192
- Run by
- Peking University People's Hospital
See details and how to joinNCT07597395 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Where
- Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan, Wuxi, Zhenjiang
- Életkor
- 18 év and over
- People
- 69 worldwide
- Run by
- argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00 - 3. fázisTaking peopleHigh-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
- Where
- Jinan
- Életkor
- 18 év to 80 év
- People
- 86
- Run by
- Shandong University
See details and how to joinNCT07559331 - 4. fázisTaking peopleEltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
- Where
- Tianjin
- Életkor
- 18 év to 60 év
- People
- 224
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT04518475 - Korai 1. fázisTaking peopleUCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 27
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07441525 - Korai 1. fázisNot yet taking people in KínaA Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 27
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07416032 - 2. fázisTaking peopleRituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 160
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07234019 - 2. fázisTaking peopleAnti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 160
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07297563 - 2. fázisNot yet taking people in KínaPhase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 28
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07400250